Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

NCT06939036 PHASE1, PHASE2 TERMINATED

This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Details

Lead sponsor	Ariceum Therapeutics GmbH
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	2
Start date	Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Small Cell Lung Cancer Extensive Stage
• Merkel Cell Carcinoma

Interventions

• 225Ac-SSO110 + SoC
• Atezolizumab
• Durvalumab
• Avelumab
• Pembrolizumab
• Retifanlimab

Countries

United States, Australia